ViaDerma Inc. (OTC:VDRM) Enters the Billion Dollar Medical Marijuana Industry with a Patent Pending CBD Delivery System

ViaDerma Inc. Is Entering A Legal Cannabis Market That Will See A Whopping $21.8 billion In Total Annual Sales By 2020.


Nutley, NJ -- (ReleaseWire) -- 11/29/2016 --ViaDerma, Inc. (OTCPINK:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced the Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.

Viaderma's technology is pretty revolutionary, and if the company can carry it through to commercialization in any number of potential indications, there's an opportunity for substantial revenues. There's precedent for this sort of technology to drive upside momentum, as well. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) went from as little as $0.0045 to $0.2 between late September and late October. That's a 10X multiple of the gains we've just seen in ViaDerma, on a very similar technology (topical administration and sublingual CBD). It seems markets are bullish on this sort of administration taking a big chunk of the future healthcare space, and even more so when it comes to CBD target indications.

The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. ViaDerma also has Viabecline, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.

Market for the following Drugs:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema- $2.5 billion in 2014

ViaDerma Inc. (OTCPINK:VDRM) sees the use of CBD's along with our Proprietary transdermal delivery system for the treatment and continuing studies look very promising and demonstrate efficacy in terms of treating several unrelated diseases. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Christopher Otiko, ViaDerma's founder and CEO.

About ViaDerma, Inc.
ViaDerma, Inc. (OTCPINK:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStemâ„¢, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets.

For more information visit: